Otwarty dostęp

Sunitinib potentiates the cytotoxic effect of electrochemotherapy in pancreatic carcinoma cells

Masa Bosnjak
Masa Bosnjak
, 
Tanja Jesenko
Tanja Jesenko
, 
Bostjan Markelc
Bostjan Markelc
, 
Anja Cerovsek
Anja Cerovsek
, 
Gregor Sersa
Gregor Sersa
 oraz 
Maja Cemazar
Maja Cemazar
   | 28 mar 2022
Radiology and Oncology's Cover Image
O artykule
Poprzedni artykuł
Następny artykuł
Zacytuj
Article Category: Research Article
Data publikacji: 28 mar 2022
Zakres stron: 164 - 172
Otrzymano: 10 lut 2022
Przyjęty: 02 mar 2022
DOI: https://doi.org/10.2478/raon-2022-0009
© 2022 Masa Bosnjak, Tanja Jesenko, Bostjan Markelc, Anja Cerovsek, Gregor Sersa, Maja Cemazar, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1

Survival fraction of BxPC-3 cells after electrochemotherapy (ECT). Survival of cells treated with ECT with bleomycin after 3 days (A) and 7 days (B) and survival fraction of BxPC-3 cells treated with ECT with cisplatin after 3 (C) and 7 days (D). The values are presented as the AM ± SEM. *p < 0.05 vs. untreated control cells, n = 3.
Survival fraction of BxPC-3 cells after electrochemotherapy (ECT). Survival of cells treated with ECT with bleomycin after 3 days (A) and 7 days (B) and survival fraction of BxPC-3 cells treated with ECT with cisplatin after 3 (C) and 7 days (D). The values are presented as the AM ± SEM. *p < 0.05 vs. untreated control cells, n = 3.

Figure 2

Targeted therapy of BxPC-3 pancreatic carcinoma cells with sunitinib. (A) Expression of different tyrosine kinases as sunitinib targets; n = 2. Surviving fraction of BxPC-3 cells treated with different sunitinib concentrations incubated for (B) 3 and (C) 7 days. The values are presented as the AM ± SEM. *p < 0.05 vs. untreated control cells, n = 3. FLT1 = fms related receptor tyrosine kinase 1/VEGFR1; FLT3 = fms related receptor tyrosine kinase 3; KDR = kinase insert domain receptor/VEGFR2; KIT = KIT proto-oncogene; RET = ret proto-oncogene; PDGFR = platelet-derived growth factor receptor
Targeted therapy of BxPC-3 pancreatic carcinoma cells with sunitinib. (A) Expression of different tyrosine kinases as sunitinib targets; n = 2. Surviving fraction of BxPC-3 cells treated with different sunitinib concentrations incubated for (B) 3 and (C) 7 days. The values are presented as the AM ± SEM. *p < 0.05 vs. untreated control cells, n = 3. FLT1 = fms related receptor tyrosine kinase 1/VEGFR1; FLT3 = fms related receptor tyrosine kinase 3; KDR = kinase insert domain receptor/VEGFR2; KIT = KIT proto-oncogene; RET = ret proto-oncogene; PDGFR = platelet-derived growth factor receptor

Figure 3

Surviving fraction of BxPC-3 cells treated with ECT monotherapy with bleomycin (A) or cisplatin (B) combined with 2.5, 5 or 7.5 μM sunitinib. The values are presented as the AM ± SEM. *p < 0.05 statistically significant difference vs. annotated groups, n = 3.
Surviving fraction of BxPC-3 cells treated with ECT monotherapy with bleomycin (A) or cisplatin (B) combined with 2.5, 5 or 7.5 μM sunitinib. The values are presented as the AM ± SEM. *p < 0.05 statistically significant difference vs. annotated groups, n = 3.

Figure 4

The combination of ECT with bleomycin and sunitinib resulted in a higher number of dead cells. (A) Number of dead cells detected every 4 hours during kinetic measurement (A) after ECT single treatment, (B) after addition of 2.5, 5 or 7.5 μM sunitinib to Ctrl, (C) after addition of 2.5, 5 or 7.5 μM sunitinib to EP and (D) after addition of 2.5, 5 or 7.5 μM sunitinib to ECT. The values are presented as the AM ± SEM. *p < 0.05 vs. annotated groups, n = 3. Ctrl = untreated control cells; ECT = electrochemotherapy; EP = electroporated cells only
The combination of ECT with bleomycin and sunitinib resulted in a higher number of dead cells. (A) Number of dead cells detected every 4 hours during kinetic measurement (A) after ECT single treatment, (B) after addition of 2.5, 5 or 7.5 μM sunitinib to Ctrl, (C) after addition of 2.5, 5 or 7.5 μM sunitinib to EP and (D) after addition of 2.5, 5 or 7.5 μM sunitinib to ECT. The values are presented as the AM ± SEM. *p < 0.05 vs. annotated groups, n = 3. Ctrl = untreated control cells; ECT = electrochemotherapy; EP = electroporated cells only
eISSN:
1581-3207
Język:
Angielski
Częstotliwość wydawania:
4 razy w roku
Dziedziny czasopisma:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Kanał RSS czasopisma